REGN
Regeneron Pharmaceuticals
PEG ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: REGN
- PEG Ratio
REGN currently has a PEG ratio reading of 45.45 as of Jul 31, 2026. This value reflects a P/E ratio of 18.18 measured against EPS growth of 0.4%. When compared to the trailing four-quarter average of 19.0, REGN's PEG ratio shows a 139% increase.
REGN PEG ratio history
A ten years lookback shows an average PEG ratio of 6.08 for Regeneron Pharmaceuticals. Compared to historical data, REGN's 45.45 PE to growth ratio represents a rise of 648%. REGN reached its maximum PEG ratio of 86.9 during the Jun 2024 quarter over the past ten years. The Dec 2021 quarter had the bottom reading at 0.06, indicating the most optimal growth-adjusted valuation.
Regeneron Pharmaceuticals PEG ratio by year
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 3.38 | 17.92 | 5.3% |
| 2024 | 1.68 | 17.42 | 10.4% |
| 2023 | N/A | 23.71 | -8.5% |
| 2022 | N/A | 17.81 | -47% |
| 2021 | 0.06 | 8.27 | 134% |
| 2020 | 0.22 | 14.8 | 68.5% |
| 2019 | N/A | 19.37 | -14.4% |
| 2018 | 0.16 | 16.49 | 101% |
| 2017 | 1.05 | 33.36 | 31.8% |
| 2016 | 1.11 | 42.93 | 38.6% |
| 2015 | 1.05 | 87.99 | 83.6% |
| 2014 | N/A | 122.1 | -20.6% |
| 2013 | N/A | 65.07 | -46.6% |
| 2012 | 0.05 | 21.6 | 423.3% |
| 2011 | N/A | N/A | -94.4% |
Regeneron Pharmaceuticals PEG ratio by quarter (TTM)
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Jun 2026 | 37.18 | 14.87 | 0.4% |
| Mar 2026 | 9.55 | 18.15 | 1.9% |
| Dec 2025 | 3.38 | 17.92 | 5.3% |
| Sep 2025 | 25.88 | 12.94 | 0.5% |
| Jun 2025 | 3.49 | 12.57 | 3.6% |
| Mar 2025 | 0.97 | 15.18 | 15.6% |
| Dec 2024 | 1.68 | 17.42 | 10.4% |
| Sep 2024 | 1.55 | 24.31 | 15.7% |
| Jun 2024 | 86.9 | 26.07 | 0.3% |
| Mar 2024 | N/A | 26.65 | -7.5% |
| Dec 2023 | N/A | 23.71 | -8.5% |
| Sep 2023 | N/A | 22.02 | -25.7% |
| Jun 2023 | N/A | 17.87 | -24.7% |
| Mar 2023 | N/A | 21.04 | -47.9% |
| Dec 2022 | N/A | 17.81 | -47% |
REGN average PEG ratio chart
Measured against past performance, REGN's PEG ratio is higher than its 3, 5 and 10-year averages.
PEG comparison
With a PEG of 45.45, REGN is above the Healthcare sector and the industry average.
REGN EPS growth
REGN Price vs fair value
REGN PEG vs peers
REGN has a PEG ratio above that of peer stocks AMGN and ALNY.
| Stock name | PEG ratio | Market cap |
|---|---|---|
| ALNY Alnylam Pharmaceuticals Inc | 0.09 | $28.93B |
| AMGN AMGEN Inc | 0.84 | $203.51B |
| REGN Regeneron Pharmaceuticals Inc | 45.45 | $78.5B |
| BIIB Biogen Inc | N/A | $29.77B |
| NVS Novartis AG | N/A | $291.81B |
| JNJ Johnson & Johnson | N/A | $609.45B |
Frequently asked questions
What is Regeneron Pharmaceuticals's PEG ratio?
REGN's Jul 31, 2026 PEG ratio comes in at 45.45.
What is the 3-year average PEG ratio for Regeneron Pharmaceuticals (REGN)?
Over the last 3 years, REGN's PEG ratio has settled near 18.95.
What is the 5-year average PEG ratio for Regeneron Pharmaceuticals (REGN)?
Over the last 5 years, REGN's PEG ratio has settled near 14.23.
What is the highest PEG ratio for REGN?
In the last ten years, REGN's peak PEG ratio of 86.9 was recorded in the Jun 2024 quarter.
How does the current PEG ratio for REGN compare to its historical average?
Currently, REGN's PEG ratio stands 648% higher than its 10-year historical average.
Why is Regeneron Pharmaceuticals's PEG ratio so high?
Slow earnings growth combined with a high valuation pushes REGN's PEG ratio to 45.45.
How is REGN's PEG ratio calculated (Regeneron Pharmaceuticals PEG ratio formula)?
Computing the PEG ratio involves dividing the PE ratio by the company's EPS growth (YoY TTM). As of Jul 31, 2026, Regeneron Pharmaceuticals has a P/E ratio of 18.18. Earnings grew at 0.4% over the TTM period ending Jun 2026. Applying the formula, this produces a price to earnings growth ratio of 45.45. PEG RATIO(45.45) = PE RATIO(18.18) / EPS GROWTH(0.4%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.